Sol-Gel Reports Q1 Revenue of $108,000
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2026
0mins
Reports Q1 revenue $108,000 vs. $1.03M last year. Mori Arkin, executive chairman of Sol-Gel, stated: "The first quarter of 2026 was a period of substantial progress on every front that matters to Sol-Gel. The Notice of Allowance extending the exclusivity of patidegib until 2044 marks a major milestone in the value creation of SGT-610 and Sol-Gel as a company. In parallel, the successful completion of our oversubscribed offering, with broad participation from leading healthcare specialist investors, is expected to provide Sol-Gel with the financial resources to support operations into 2028, allowing us to execute our Phase 3 program of SGT-610 through top-line readout and to support its pre-commercialization activities."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLGL
Wall Street analysts forecast SLGL stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 74.120
Low
50.00
Averages
50.00
High
50.00
Current: 74.120
Low
50.00
Averages
50.00
High
50.00
About SLGL
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- Citi Upgrade: Citi upgraded Macerich from Neutral to Buy, raising the target price from $24 to $28, indicating strong balance sheet strength that is expected to drive stock price appreciation.
- Citizens Initiation: Citizens initiated coverage on Bitdeer Holdings and Mara Holdings, stating that these bitcoin miners have significant potential to outperform the market by repurposing existing power capacity for high-performance computing.
- Mizuho's Biotech Outlook: Mizuho initiated coverage of Sol-Gel Technologies with an Outperform rating and a $285 price target, suggesting that the biotech firm is well-positioned for future growth in a competitive landscape.
- Goldman on Twilio: Goldman Sachs initiated coverage of Twilio with a Buy rating and a 12-month price target of $300, highlighting expected margin upside that reflects strong confidence in the company's financial prospects.
See More
Sol-Gel Technologies Q1 Financial Results Show Revenue Decline
- Revenue Decline: Sol-Gel Technologies reported Q1 revenue of $0.1 million, a significant drop from $1.0 million in the same period of 2025, primarily due to the absence of a milestone payment from Searchlight that was received in Q1 2025, which has constrained the company's cash flow and impacted future investment capabilities.
- Earnings Per Share Loss: The company reported an EPS loss of $1.31, indicating that operational costs have not been effectively controlled amidst declining revenues, which may heighten investor concerns regarding the company's financial health.
- Financing Plan: Sol-Gel Technologies announced a financing plan to raise over $33 million at a price of $72 per share, aiming to enhance liquidity; despite the current financial challenges, successful financing could provide necessary funds for future R&D and market expansion.
- Market Attention: In March, Sol-Gel Technologies was highlighted as one of the most and least shorted healthcare stocks, reflecting market divergence regarding its future performance, prompting investors to closely monitor subsequent financial results and strategic adjustments.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Sol-Gel Technologies Prices Oversubscribed Public Offering
- Successful Offering: Sol-Gel Technologies announced the pricing of its oversubscribed public offering, reflecting strong investor interest in its dermatology pipeline, with proceeds aimed at working capital and supporting ongoing clinical development, particularly late-stage trials of its lead program.
- Clinical Progress: SGT-610 (Patidegib gel, 2%) is currently in Phase 3 trials aimed at preventing new basal cell carcinomas in Gorlin syndrome patients, with top-line results expected in Q4 2026, and if approved, it could become the first preventive treatment for this condition.
- Market Opportunity: The Phase 2 trial for SGT-610 targeting high-frequency basal cell carcinoma is planned to start between H2 2027 and H1 2028, focusing on patients who develop multiple BCCs over their lifetime, representing a significant market opportunity.
- Product Portfolio: The FDA-approved products TWYNEO and EPSOLAY provide a commercial foundation as the company advances its earlier-stage candidates, with TWYNEO combining two established agents and EPSOLAY treating inflammatory lesions of rosacea, supported by multiple commercial agreements across four continents.
See More
Sol-Gel Technologies Raises $33.1M in Oversubscribed Offering
- Offering Size: Sol-Gel Technologies successfully priced an oversubscribed public offering of approximately 459,000 shares at $72.00 each, raising about $33.1 million, indicating strong market demand despite a 9% drop in stock price during the same period.
- Use of Proceeds: The funds will be allocated to the continued development of SGT-610, including pre-commercialization activities and R&D, aimed at preventing new basal cell carcinomas in patients with Gorlin syndrome, thereby enhancing the company's competitive edge in skin cancer treatment.
- Market Reaction: Despite the successful fundraising, Sol-Gel's stock price fell to $66.20 during pre-market trading on Tuesday, reflecting investor concerns about the company's future performance, particularly its reliance on upcoming Q4 catalysts.
- Future Outlook: The offering is expected to close around March 25, 2026, and if SGT-610's development proceeds smoothly, it could present new growth opportunities for the company; however, market confidence in its success still needs to be validated through the upcoming earnings report.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
Latest Wall Street Rating Updates
- Citi Upgrade: Citi upgraded Macerich from Neutral to Buy, raising the target price from $24 to $28, indicating strong balance sheet strength that is expected to drive stock price appreciation.
- Citizens Initiation: Citizens initiated coverage on Bitdeer Holdings and Mara Holdings, stating that these bitcoin miners have significant potential to outperform the market by repurposing existing power capacity for high-performance computing.
- Mizuho's Biotech Outlook: Mizuho initiated coverage of Sol-Gel Technologies with an Outperform rating and a $285 price target, suggesting that the biotech firm is well-positioned for future growth in a competitive landscape.
- Goldman on Twilio: Goldman Sachs initiated coverage of Twilio with a Buy rating and a 12-month price target of $300, highlighting expected margin upside that reflects strong confidence in the company's financial prospects.
See More
Sol-Gel Technologies Q1 Financial Results Show Revenue Decline
- Revenue Decline: Sol-Gel Technologies reported Q1 revenue of $0.1 million, a significant drop from $1.0 million in the same period of 2025, primarily due to the absence of a milestone payment from Searchlight that was received in Q1 2025, which has constrained the company's cash flow and impacted future investment capabilities.
- Earnings Per Share Loss: The company reported an EPS loss of $1.31, indicating that operational costs have not been effectively controlled amidst declining revenues, which may heighten investor concerns regarding the company's financial health.
- Financing Plan: Sol-Gel Technologies announced a financing plan to raise over $33 million at a price of $72 per share, aiming to enhance liquidity; despite the current financial challenges, successful financing could provide necessary funds for future R&D and market expansion.
- Market Attention: In March, Sol-Gel Technologies was highlighted as one of the most and least shorted healthcare stocks, reflecting market divergence regarding its future performance, prompting investors to closely monitor subsequent financial results and strategic adjustments.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
Sol-Gel Technologies Prices Oversubscribed Public Offering
- Successful Offering: Sol-Gel Technologies announced the pricing of its oversubscribed public offering, reflecting strong investor interest in its dermatology pipeline, with proceeds aimed at working capital and supporting ongoing clinical development, particularly late-stage trials of its lead program.
- Clinical Progress: SGT-610 (Patidegib gel, 2%) is currently in Phase 3 trials aimed at preventing new basal cell carcinomas in Gorlin syndrome patients, with top-line results expected in Q4 2026, and if approved, it could become the first preventive treatment for this condition.
- Market Opportunity: The Phase 2 trial for SGT-610 targeting high-frequency basal cell carcinoma is planned to start between H2 2027 and H1 2028, focusing on patients who develop multiple BCCs over their lifetime, representing a significant market opportunity.
- Product Portfolio: The FDA-approved products TWYNEO and EPSOLAY provide a commercial foundation as the company advances its earlier-stage candidates, with TWYNEO combining two established agents and EPSOLAY treating inflammatory lesions of rosacea, supported by multiple commercial agreements across four continents.
See More
Sol-Gel Technologies Raises $33.1M in Oversubscribed Offering
- Offering Size: Sol-Gel Technologies successfully priced an oversubscribed public offering of approximately 459,000 shares at $72.00 each, raising about $33.1 million, indicating strong market demand despite a 9% drop in stock price during the same period.
- Use of Proceeds: The funds will be allocated to the continued development of SGT-610, including pre-commercialization activities and R&D, aimed at preventing new basal cell carcinomas in patients with Gorlin syndrome, thereby enhancing the company's competitive edge in skin cancer treatment.
- Market Reaction: Despite the successful fundraising, Sol-Gel's stock price fell to $66.20 during pre-market trading on Tuesday, reflecting investor concerns about the company's future performance, particularly its reliance on upcoming Q4 catalysts.
- Future Outlook: The offering is expected to close around March 25, 2026, and if SGT-610's development proceeds smoothly, it could present new growth opportunities for the company; however, market confidence in its success still needs to be validated through the upcoming earnings report.
See More
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
- Stock Performance: Palvella Therapeutics saw its stock surge from $25 on March 10, 2025, to a 52-week high of $114.69 on December 22, 2025, reflecting strong market potential in rare disease treatments.
- Product Development: Its lead product, QTORIN rapamycin, targets microcystic lymphatic malformations and other rare diseases, with potential FDA approval expected to unlock a multi-billion-dollar market opportunity, further solidifying the company's position in the biopharmaceutical sector.
- Acquisition Activity: Cidara Therapeutics agreed to be acquired by Merck for $221.50 per share, totaling approximately $9.2 billion, with the deal expected to close in Q1 2026, highlighting major pharmaceutical interest in innovative therapies.
- Clinical Progress: Celcuity's Gedatolisib submitted a New Drug Application to the FDA in November 2025 for HR+, HER2- advanced breast cancer, which, if approved, would significantly enhance its competitive edge in the oncology market.
See More
